San Gallicano Dermatological Institute, Roma Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01382589
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

San Gallicano Dermatological Institute, Photodermatology Unit, Roma, ITALY

Active Ingredients

Drugs in Phase 2 Trials (1)

afamelanotide (Scenesse) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Vitiligo (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1